EpiPaws, Inc.

Based in Florida, US, and founded in 2022 by Andria Beal, EpiPaws, Inc. is a biotechnology company that develops epigenetic biomarkers for age and early disease detection related to pets. In December 2024, EpiPaws, Inc. raised USD 0.

25 million in venture funding. EpiPaws provides a pet age testing service designed to accurately estimate the age of dogs and cats. Utilizing advanced epigenetic sequencing technology, the company offers a pet age test that can determine a pet's age within one year of their actual age. This service is particularly beneficial for pet owners, shelters, and veterinarians, as understanding a pet's age is crucial for tailored health assessments and care strategies.

The core product is the pet age testing kit, which allows users to collect a DNA sample from their pet using a mouth swab and send it back for analysis to receive results within 4-6 weeks. EpiPaws primarily serves the North American market, focusing on pet owners who have adopted rescue pets and require age estimates for better health management. EpiPaws operates on a direct-to-consumer model, generating revenue through the sale of its pet age testing kits priced at USD 105. Customers purchase the kits online, and the business transaction involves the user collecting a DNA sample and sending it to EpiPaws for analysis.

In July 2025, EpiPaws, Inc. raised an undisclosed amount of venture funding from new investor New World Angels. The company will use the funding to accelerate research, scale its epigenetic testing services, and launch a direct-to-consumer diagnostic product for pet health.